Don A. Stevens
Expertise in
59
conditions

Dr. Don A. Stevens

Hematology Oncology
3991 Dutchmans Lane, Suite 405, 
Louisville, KY 
Accepting New Patients
44 Years of Experience
Expertise in
59
conditions
3991 Dutchmans Lane, Suite 405, 
Louisville, KY 

Overview

Don Stevens is a Hematologist Oncology provider practicing medicine in Louisville, Kentucky. He has been practicing medicine for over 44 years.

Dr. Stevens is highly rated in 59 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Follicular Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Aspiration, and Ureteroscopy.

Dr. Stevens is board certified in American Board Of Internal Medicine, Medical Oncology - 1989 and American Board Of Internal Medicine, Internal Medicine - 1986. He is actively involved in clinical research, co-authoring 70 peer reviewed articles and participating in 25 clinical trials. Dr. Stevens is currently accepting new patients.

Graduate Institution

University Of Louisville School Of Medicine, Doctor Of Medicine, 1982

Residency

University of Louisville School of Medicine, Internal Medicine, 1986

Specialties

Hematology Oncology

Licenses

Internal Medicine in KY

Board Certifications

American Board Of Internal Medicine, Medical Oncology - 1989
American Board Of Internal Medicine, Internal Medicine - 1986

Fellowships

Johns Hopkins Hospital, Medical Oncology, 1988
Johns Hopkins Hospital, Medical Oncology, 1987

Hospital Affiliations

Norton Hospitals, Inc
Baptist Health Louisville

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Ambetter
  • EPO
  • HMO
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Essence Healthcare
  • INSURANCE PLAN
  • MEDICARE MAPD
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Health Services
  • EPO
  • MANAGED MEDICAID PLAN
  • OTHER COMMERCIAL
Managed Medicaid
  • OTHER MANAGED MEDICAID
MDwise
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
MHS
  • EPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 14 Less Insurance Carriers -

Locations

Norton Cancer Institute - St. Matthews
3991 Dutchmans Lane, Suite 405, Louisville, KY 40207

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

22 Clinical Trials

A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Drug, Biological, Procedure, Other, Radiation
Study Drugs: Brentuximab, Dacarbazine, Doxorubicin, Filgrastim, Nivolumab, Pegfilgrastim, Vinblastine
Study Phase: Phase 3
An Open-label Phase II Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Tirabrutinib in Patients With Primary Central Nervous System Lymphoma (PCNSL)
An Open-label Phase II Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Tirabrutinib in Patients With Primary Central Nervous System Lymphoma (PCNSL)
Enrollment Status: Active_not_recruiting
Publish Date: March 30, 2026
Intervention Type: Drug
Study Phase: Phase 2
IELSG37: A Randomized, Open-label, Multicentre, Two-arm Phase III Comparative Study Assessing the Role of Involved Mediastinal Radiotherapy After Rituximab Containing Chemotherapy Regimens to Patients With Newly Diagnosed Primary Mediastinal Large B-Cell Lymphoma (PMLBCL)
IELSG37: A Randomized, Open-label, Multicentre, Two-arm Phase III Comparative Study Assessing the Role of Involved Mediastinal Radiotherapy After Rituximab Containing Chemotherapy Regimens to Patients With Newly Diagnosed Primary Mediastinal Large B-Cell Lymphoma (PMLBCL)
Enrollment Status: Active_not_recruiting
Publish Date: January 15, 2026
Intervention Type: Radiation, Other
Study Phase: Not Applicable
A Phase 1 Study of agenT-797 to Treat Moderate to Severe Acute Respiratory Syndrome in COVID-19 Patients
A Phase 1 Study of agenT-797 to Treat Moderate to Severe Acute Respiratory Syndrome in COVID-19 Patients
Enrollment Status: Completed
Publish Date: December 30, 2025
Intervention Type: Drug
Study Drug: AgenT-797
Study Phase: Phase 1
A Randomized, Open-label, Controlled, Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults With Newly Diagnosed Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy
A Randomized, Open-label, Controlled, Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults With Newly Diagnosed Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy
Enrollment Status: Completed
Publish Date: October 21, 2025
Intervention Type: Drug
Study Drugs: Pevonedistat, Venetoclax, Azacitidine
Study Phase: Phase 2
An Open-label, Phase 1b/2 Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma
An Open-label, Phase 1b/2 Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: October 15, 2025
Intervention Type: Drug
Study Drugs: Acalabrutinib, Rituximab, Lenalidomide
Study Phase: Phase 1/Phase 2
Open-label, Single-Arm, Phase 2 Study of Oral HDAC-inhibitor Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma (FORERUNNER)
Open-label, Single-Arm, Phase 2 Study of Oral HDAC-inhibitor Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma (FORERUNNER)
Enrollment Status: Active_not_recruiting
Publish Date: April 10, 2025
Intervention Type: Drug
Study Drug: Abexinostat
Study Phase: Phase 2
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Enrollment Status: Completed
Publish Date: March 30, 2025
Intervention Type: Drug
Study Drugs: Zanubrutinib, Ibrutinib
Study Phase: Phase 3
A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting
A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting
Enrollment Status: Completed
Publish Date: February 27, 2025
Intervention Type: Biological
Study Drug: lisocabtagene maraleucel
Study Phase: Phase 2
Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin &Amp; Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age >/= 60 Years)
Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin &Amp; Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age >/= 60 Years)
Enrollment Status: Completed
Publish Date: December 13, 2024
Intervention Type: Drug, Other, Procedure
Study Drugs: Clofarabine, Daunorubicin, Cytarabine, Decitabine
Study Phase: Phase 3
View 9 Less Clinical Trials

58 Total Publications

Benefit of selinexor dose reduction on outcomes with selinexor, bortezomib and dexamethasone in patients with lenalidomide-refractory multiple myeloma: Subgroup analysis of the BOSTON trial.
Benefit of selinexor dose reduction on outcomes with selinexor, bortezomib and dexamethasone in patients with lenalidomide-refractory multiple myeloma: Subgroup analysis of the BOSTON trial.
Journal: British journal of haematology
Published: November 24, 2025
Similar Doctors
Expertise in
26
conditions
Dr. Adam D. Lye
Hematology Oncology
Expertise in
26
conditions
Dr. Adam D. Lye
Hematology Oncology

Norton Cancer Institute - Brownsboro

4955 Norton Healthcare Boulevard, 
Louisville, KY 
 (5.4 miles away)
502-394-6350
Experience:
19+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Adam Lye is a Hematologist Oncology provider practicing medicine in Louisville, Kentucky. He has been practicing medicine for over 19 years. Dr. Lye is highly rated in 26 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Pleuropulmonary Blastoma, Non-Small Cell Lung Cancer (NSCLC), and Small Cell Lung Cancer (SCLC). Dr. Lye is board certified in American Board Of Internal Medicine, Medical Oncology - 2013 and American Board Of Internal Medicine, Internal Medicine - 2010. Dr. Lye is currently accepting new patients.

Expertise in
30
conditions
Dr. Khuda D. Khan
Hematology Oncology
Expertise in
30
conditions
Dr. Khuda D. Khan
Hematology Oncology

Norton Cancer Institute - Audubon

2355 Poplar Level Road, Suite 405, 
Louisville, KY 
 (5.1 miles away)
502-636-7845
Experience:
26+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Khuda Khan is a Hematologist Oncology provider practicing medicine in Louisville, Kentucky. He has been practicing medicine for over 26 years. Dr. Khan is highly rated in 30 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Pleuropulmonary Blastoma, Small Cell Lung Cancer (SCLC), and Posterior Fossa Tumor. Dr. Khan is currently accepting new patients.

Expertise in
19
conditions
Dr. Padmini U. Moffett
Hematology Oncology
Expertise in
19
conditions
Dr. Padmini U. Moffett
Hematology Oncology

University Of Louisville Physicians - Oncology

529 South Jackson Street, 
Louisville, KY 
 (6.1 miles away)
502-562-4673
Experience:
24+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Padmini Moffett is a Hematologist Oncology provider practicing medicine in Louisville, Kentucky. She has been practicing medicine for over 24 years. Dr. Moffett is highly rated in 19 conditions, according to our data. Her clinical expertise encompasses Ependymoma, Gliosarcoma, Glioblastoma, and Embryonal Tumor with Multilayered Rosettes. Dr. Moffett is board certified in American Board Of Internal Medicine, Medical Oncology - 2008 , American Board Of Internal Medicine, Hematology - 2008 , and American Board Of Internal Medicine, Internal Medicine - 2005. Dr. Moffett is currently accepting new patients.

Frequently Asked Questions about Dr. Don A. Stevens

How do I make an appointment with Dr. Don A. Stevens?

You can book an appointment with Dr. Don A. Stevens by calling their office at 502-899-3366. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Don A. Stevens a top-rated expert for Non-Hodgkin Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Don A. Stevens is classified as an Elite expert for Non-Hodgkin Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Don A. Stevens specialize in?

While Dr. Don A. Stevens is a Hematology Oncology, they have specific expertise in Non-Hodgkin Lymphoma, Follicular Lymphoma, and Diffuse Large B-Cell Lymphoma (DLBCL). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology Oncology.

Does Dr. Don A. Stevens participate in research or clinical trials?

Yes. Dr. Don A. Stevens has published 58 articles and abstracts on conditions like Non-Hodgkin Lymphoma. You can view a list of Dr. Don A. Stevens's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Don A. Stevens accept my insurance?

Dr. Don A. Stevens accepts most major insurance plans, including Aetna and Ambetter. We recommend calling the office directly at 502-899-3366 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Stevens's expertise for a condition
ConditionClose
View All 25 Distinguished Conditions
View All 33 Advanced Conditions
View All 69 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile